We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETNB
26
DELISTED
89bio
ETNB
$5.85M 1.09%
804,220
+289,082
+56% +$2.53M
NVS icon
27
PUT
Novartis
NVS
$293B
$5.57M 1.03%
+50,000
New +$5.32M
OACCU
28
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$5.39M 1%
516,482
+16,482
+3% +$168K
BBOT
29
BridgeBio Oncology
BBOT
$703M
$5.31M 0.99%
469,729
+65,591
+16% +$705K
AMLX icon
30
Amylyx Pharmaceuticals
AMLX
$2.69B
$5.21M 0.97%
+1,471,587
New +$5.24M
SRRK icon
31
Scholar Rock
SRRK
$6.31B
$5.05M 0.94%
157,079
+137,574
+705% +$5.29M
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.24B
$4.28M 0.79%
127,548
+77,001
+152% +$2.92M
XNCR icon
33
Xencor
XNCR
$1.48B
$4.24M 0.79%
398,152
+163,545
+70% +$2.7M
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.38B
$4.18M 0.78%
263,425
-578,116
-69% -$6.65M
SEPN
35
Septerna Inc
SEPN
$1.78B
$4.17M 0.77%
+720,848
New +$8.23M
JANX icon
36
Janux Therapeutics
JANX
$982M
$4.15M 0.77%
153,767
+122,258
+388% +$4.61M
APGE icon
37
Apogee Therapeutics
APGE
$10.2B
$3.92M 0.73%
104,853
+63,579
+154% +$2.46M
SVRA icon
38
Savara
SVRA
$1.19B
$3.77M 0.7%
1,360,291
+371,823
+38% +$1.03M
MNPR icon
39
Monopar Therapeutics
MNPR
$805M
$3.67M 0.68%
100,774
-29,263
-23% -$1.05M
JBIO
40
Jade Biosciences
JBIO
$1.35B
$3.67M 0.68%
41,750
+15,235
+57% +$1.34M
BIOA
41
BioAge Labs
BIOA
$501M
$3.65M 0.68%
971,100
+848,063
+689% +$3.92M
ZURA icon
42
Zura Bio
ZURA
$542M
$3.61M 0.67%
2,801,184
+723,933
+35% +$1.14M
SLNO
43
PUT
DELISTED
Soleno Therapeutics
SLNO
$3.57M 0.66%
+50,000
New +$2.43M
ATXS
44
DELISTED
Astria Therapeutics
ATXS
$3.43M 0.64%
641,690
+550,706
+605% +$3.85M
RZLT icon
45
Rezolute
RZLT
$453M
$3.24M 0.6%
1,116,047
-243,161
-18% -$1.06M
CNTA
46
DELISTED
Centessa Pharmaceuticals
CNTA
$3.11M 0.58%
216,166
+62,139
+40% +$1.02M
AKRO
47
DELISTED
Akero Therapeutics
AKRO
$2.88M 0.53%
71,143
+55,836
+365% +$2.37M
MRUS
48
DELISTED
Merus
MRUS
$2.82M 0.52%
66,960
-14,500
-18% -$632K
PTCT icon
49
PTC Therapeutics
PTCT
$5.91B
$2.55M 0.47%
50,023
+2,000
+4% +$99.8K
RGNX icon
50
Regenxbio
RGNX
$722M
$2.51M 0.47%
350,352
+180,223
+106% +$1.34M
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.